The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Biomarker-guided treatment selection in frontline CLL: the role of IGHV and TP53 status
Thomas Chatzikonstantinou, MD, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses the role of biomarkers in guiding the management of chronic lymphocytic leukemia (CLL), highlighting that IGHV gene somatic hypermutation status and TP53 aberrations are crucial in selecting first-line therapy. Dr Chatzikonstantinou emphasizes the importance of using fluorescent in situ hybridisation (FISH) for 17p deletion and sequencing methods for detecting TP53 mutations, in order to decide between continuous and fixed duration treatments. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
